QP1: Development of PharmPAL: A Collaborative Practice Pharmacy Clinic in an Ambulatory Care Clinic

Abstract

Background:

As authoritative resources on the optimal use of medications in symptom management, palliative care pharmacists exemplify several clinical, administrative, and educational roles within the outpatient clinic setting. Knowledge of medication-use processes allows pharmacists the ability to improve patient safety and outcomes. In 2018 a quality improvement project to optimize the scheduling of pharmacist-provider joint visits in the Dana-Farber Cancer Institute Outpatient Palliative Care Clinic led to overwhelming Adult Palliative Care (APC) provider satisfaction. Given this success and continued desire for pharmacy collaboration, the “PharmPAL” Clinic was initiated in July of 2020. PharmPAL is a collaborative drug therapy management (CDTM) clinic where credentialed pharmacists lead intermediary and follow-up palliative care visits encompassing patient assessments, counseling, education, ordering of laboratory tests, and selecting, initiating, continuing, and modifying medication regimens. The goal of PharmPAL is to support the growth of the palliative care clinic by providing care to patients with intense symptom management needs through interval visits with a pharmacist within their credentialed scope of practice, increasing the availability of follow-up to patients.

Methods:

Through a survey disseminated to all outpatient palliative care providers, reasons for referral for both joint visits and PharmPAL visits were gathered. Based on an overwhelming percentage of providers in favor of increasing PharmPAL visits, the weekly availability increased from eight 30 minute appointments per week in the first seven months to twelve 30 minute appointments each week.

Results:

The top five reasons for PharmPAL referral include new consult requiring close follow-up, education and counseling, stable patient for refill review, schedule availability, and regimen or medication change in the previous visit or anticipated in visit. Barriers to utilizing PharmPAL include pharmacist availability, APC scheduling, and out-of-state patients. An increase in PharmPAL availability has led to an increased volume of patients and encounters for both PharmPAL and the outpatient clinic overall. Additional surveys will be employed to address feedback for ongoing areas for improvement in order to reach our goal of a 30% increase of PharmPAL referrals within the first three months and continued improvement in overall provider satisfaction with PharmPAL.

Conclusion:

As outpatient palliative care clinics are incorporating pharmacist-led visits into practice, identification of outcomes metrics is critical to the ongoing growth of these clinics. Over the next several months we plan to continue to assess the impact PharmPAL has on clinic operations and provider satisfaction in the Dana-Farber Cancer Institute outpatient palliative care clinic.

Additional information

Notes on contributors

Molly Bacon

Bacon Molly is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Kematick Benjamin is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Suliman Iman is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Scullion Bridget is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Lally Kate is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic.

Benjamin Kematick

Bacon Molly is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Kematick Benjamin is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Suliman Iman is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Scullion Bridget is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Lally Kate is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic.

Iman Suliman

Bacon Molly is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Kematick Benjamin is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Suliman Iman is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Scullion Bridget is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Lally Kate is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic.

Bridget Scullion

Bacon Molly is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Kematick Benjamin is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Suliman Iman is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Scullion Bridget is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Lally Kate is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic.

Kate Lally

Bacon Molly is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Kematick Benjamin is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Suliman Iman is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Scullion Bridget is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic. Lally Kate is with Dana-Farber Cancer Institute Outpatient Palliative Care Clinic.